ACE-031 (1mg) Peptide – Premium Research Agent for Muscle Growth Studies
ACE-031, also known as Ramatercept, is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIB (ActRIIB) linked to the Fc region of human immunoglobulin G1 (IgG1) . As a myostatin inhibitor, it functions as a ligand trap that binds to myostatin and other negative regulators of muscle mass, effectively neutralizing their inhibitory effects on skeletal muscle growth.
ACE-031 Peptide (ActRIIB-IgG1) – 1mg Research Vial
Key Factual Details
| ATTRIBUTE | DETAIL |
|---|---|
| Chemical Name | ACE-031 (Ramatercept, ActRIIB-IgG1) |
| Molecular Formula (Full Protein) | C₃₄₁₈H₅₁₈₈N₉₂₈O₁₀₆₂S₃₈ |
| Molecular Weight (Full Protein) | ~77,489.89 g/mol |
| CAS Number | 1621169-52-5 |
| Product Form | Lyophilized powder |
| Purity | >98% (HPLC verified) |
| Peptide Fragment Formula | C₁₃₃H₂₂₇N₄₃O₃₃ |
| Fragment Molecular Weight | 2,956.49 g/mol |
| Classification | Recombinant fusion protein / Myostatin inhibitor |
Mechanism of Action & Research Applications
ACE-031 is a soluble form of the activin receptor type IIB that acts by binding to myostatin and other negative regulators of muscle mass . By sequestering these inhibitors, ACE-031 promotes muscle growth signaling pathways and supports increases in lean body mass .
Primary Research Applications:
-
Muscle Growth Studies: Investigates the blockade of myostatin and activin A to support skeletal muscle mass and function
-
Muscle Wasting Models: Explores therapeutic potential for conditions involving loss of skeletal muscle mass, strength, and integrity
-
Signal Transduction Research: Examines SMAD signaling pathways downstream of myostatin inhibition
-
Protein Interaction Studies: Characterizes binding dynamics between myostatin and ActRIIB receptors
-
In Vitro Muscle Modeling: Simulates altered myostatin environments to study muscle hypertrophy and atrophy
Research Dosing & Handling
All dosages are for in-vitro and preclinical research use only and not for human consumption.
Documented Research Parameters (Human Studies):
-
Single Dose Range: 0.02 mg/kg to 3 mg/kg subcutaneously
-
Study Regimens: Doses administered once every 2 to 4 weeks
-
Pharmacokinetics: Mean T₁/₂ of 10–15 days; AUC and Cmax increased linearly with dose
Observed Effects in Research:
-
3.3% increase in total body lean mass (DXA) at day 29 in the 3 mg/kg group
-
5.1% increase in thigh muscle volume (MRI) at day 29 in the 3 mg/kg group
-
Significant increase in body weight and lean body mass in non-human primate models over 14 weeks
Storage:
-
Store lyophilized powder at -20°C
-
For reconstituted solutions: store at -80°C for long-term stability
